Trial Profile

A phase IB proof-of-concept, antiviral activity, safety, and pharmacokinetics study of GS-1720

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GS 1720 (Primary)
Indications HIV infections
Focus Adverse reactions; Proof of concept

Most Recent Events

06 Mar 2024 Results (n=7) assessing antiviral activity, safety, and pharmacokinetics of GS-1720 in the first cohort dosed with 450 mg, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
05 Mar 2024 Results published in the Gilead Sciences Media Release.
05 Mar 2024 According to a Gilead Sciences media release, data from this trial were presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com